Ribomic

Ribomic Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Ribomic (4591.T) as of Oct 30, 2026 is 239.28. In the previous year, Cash Conversion Cycle (CCC) was 1,454.83 — a change of -83.55% (lower).

Cash Conversion Cycle

239.28

YoY

-83.55%

Last updated:

Cash Conversion Cycle (CCC) of Ribomic is 2026 239.28 . Cash Conversion Cycle (CCC) of Ribomic was 2025 1,454.83 . It decreases by -83.55% lower compared to the previous year.

The Ribomic Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2014
334.27 JPY
Jan 1, 2015
1.17 JPY
Jan 1, 2017
8.08 JPY
Jan 1, 2020
327.25 JPY
Jan 1, 2024
79.03 JPY
Jan 1, 2025
1,454.83 JPY
Jan 1, 2026
239.28 JPY
The Ribomic Cash Conversion Cycle history
YEARCash Conversion CycleYoY
239.28-83.55%
1,454.83+1,740.78%
79.03-75.85%
327.25+3,951.76%
8.08+593.05%
1.17-99.65%
334.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Cash Conversion Cycle (CCC) of Ribomic is 239.28 in 2026.

Cash Conversion Cycle (CCC) of Ribomic changed from 1,454.83 to 239.28, representing a -83.55% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Ribomic since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Ribomic with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Ribomic

All Key Metrics — Ribomic